Display options
Cite
Saint-Aubert L, Barbeau EJ, Péran P, et al. Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. EJNMMI Res. 2013;3(1):43doi: 10.1186/2191-219X-3-43.
Saint-Aubert, L., Barbeau, E. J., Péran, P., Nemmi, F., Vervueren, C., Mirabel, H., Payoux, P., Hitzel, A., Bonneville, F., Gramada, R., Tafani, M., Vincent, C., Puel, M., Dechaumont, S., Chollet, F., & Pariente, J. (2013). Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. EJNMMI research, 3(1), 43. https://doi.org/10.1186/2191-219X-3-43
Saint-Aubert, Laure, et al. "Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients." EJNMMI research vol. 3,1 (2013): 43. doi: https://doi.org/10.1186/2191-219X-3-43
Saint-Aubert L, Barbeau EJ, Péran P, Nemmi F, Vervueren C, Mirabel H, Payoux P, Hitzel A, Bonneville F, Gramada R, Tafani M, Vincent C, Puel M, Dechaumont S, Chollet F, Pariente J. Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. EJNMMI Res. 2013 Jun 03;3(1):43. doi: 10.1186/2191-219X-3-43. PMID: 23731789; PMCID: PMC3733998.
Copy Download .nbib Format: NLM
Share it on

EJNMMI Res. 2013 Jun 03;3(1):43. doi: 10.1186/2191-219X-3-43.

Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients.

EJNMMI research

Laure Saint-Aubert, Emmanuel J Barbeau, Patrice Péran, Federico Nemmi, Celine Vervueren, Helene Mirabel, Pierre Payoux, Anne Hitzel, Fabrice Bonneville, Raluca Gramada, Mathieu Tafani, Christian Vincent, Michele Puel, Sophie Dechaumont, Francois Chollet, Jeremie Pariente

Affiliations

  1. INSERM, Imagerie Cérébrale et Handicaps Neurologiques UMR 825, Centre Hospitalier Universitaire de Toulouse, Place Dr Baylac, Pavillon Baudot, Toulouse CEDEX 9 31059, France. [email protected].

PMID: 23731789 PMCID: PMC3733998 DOI: 10.1186/2191-219X-3-43

Abstract

BACKGROUND: Florbetapir (AV-45) has been shown to be a reliable tool to assess amyloid load in patients with Alzheimer's disease (AD) at demential stages. Longitudinal studies also suggest that AV-45 has the ability to bind amyloid in the early stages of AD. In this study, we investigated AV-45 binding and its relation with cognitive performance in a group of patients at the prodromal stage of Alzheimer's disease, recruited according to strict inclusion criteria.

METHODS: We recruited patients at the prodromal stage of AD and matched control subjects. AV-45 binding was assessed using an innovative extraction method allowing quantifying uptake in the cortex only. AV-45 uptake was compared between groups in the precuneus, posterior cingulate, anterior cingulate, and orbito-frontal regions. Correlations between AV-45 uptake and cognitive performance were assessed.

RESULTS: Twenty-two patients and 17 matched control subjects were included in the study. We report a significant increase of cortical AV-45 uptake in the patients compared to the control subjects in all regions of interest. Specific correlations were found within the patient group between mean global amyloid cortical load and cognitive performance in three different memory tests.

CONCLUSIONS: These findings suggest that at the prodromal stage of AD, memory decline is linked to an increase of cortical β-amyloid load.

References

  1. J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):967-72 - PubMed
  2. Lancet Neurol. 2012 Aug;11(8):669-78 - PubMed
  3. Arch Neurol. 2011 Sep;68(9):1137-44 - PubMed
  4. Neurobiol Aging. 2013 Mar;34(3):822-31 - PubMed
  5. J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):923-6 - PubMed
  6. Neuroimage. 2002 Jan;15(1):273-89 - PubMed
  7. Neurology. 2000 Dec 12;55(11):1621-6 - PubMed
  8. J Neurosci. 2010 Feb 10;30(6):2088-101 - PubMed
  9. Neurology. 2012 Oct 16;79(16):1636-44 - PubMed
  10. Brain. 2007 Nov;130(Pt 11):2837-44 - PubMed
  11. Neurology. 2010 Mar 9;74(10):807-15 - PubMed
  12. Ann Neurol. 2004 Mar;55(3):306-19 - PubMed
  13. Brain. 2008 Jun;131(Pt 6):1630-45 - PubMed
  14. Arch Neurol. 2011 Nov;68(11):1404-11 - PubMed
  15. JAMA. 2011 Jan 19;305(3):275-83 - PubMed
  16. Rev Neurol (Paris). 2009 Jun-Jul;165(6-7):560-7 - PubMed
  17. J Nucl Med. 2010 Jun;51(6):913-20 - PubMed
  18. Alzheimers Dement. 2011 May;7(3):270-9 - PubMed
  19. Neurobiol Aging. 2013 Jan;34(1):1-12 - PubMed
  20. Lancet Neurol. 2007 Aug;6(8):734-46 - PubMed
  21. Lancet Neurol. 2013 Apr;12(4):357-67 - PubMed
  22. Ann Neurol. 2008 Jan;63(1):112-8 - PubMed
  23. Ann Neurol. 2010 Mar;67(3):317-24 - PubMed
  24. Neurology. 2012 Feb 7;78(6):387-95 - PubMed
  25. JAMA. 2009 Jul 22;302(4):385-93 - PubMed
  26. Nucl Med Biol. 2010 May;37(4):497-508 - PubMed
  27. Lancet Neurol. 2010 Nov;9(11):1118-27 - PubMed
  28. J Neurochem. 2007 May;101(4):1053-9 - PubMed
  29. J Alzheimers Dis. 2012;30(4):847-56 - PubMed
  30. Ann Neurol. 2011 Jan;69(1):181-92 - PubMed
  31. J Neurosci. 2012 Nov 14;32(46):16265-73 - PubMed
  32. Alzheimers Dement. 2013 Oct;9(5 Suppl):S72-83 - PubMed
  33. Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):91-4 - PubMed
  34. J Alzheimers Dis. 2012;28(4):877-83 - PubMed
  35. Cerebrovasc Dis. 2002;13 Suppl 2:31-6 - PubMed
  36. Neurology. 2007 Nov 6;69(19):1859-67 - PubMed
  37. Neurology. 2004 Apr 27;62(8):1317-22 - PubMed
  38. Alzheimers Dement. 2011 May;7(3):263-9 - PubMed
  39. Brain. 2011 Apr;134(Pt 4):1077-88 - PubMed

Publication Types